Nurix Therapeutics initiated Phase 1b dose expansion of NX-5948 in CLL patients with Fast Track designation, also expanding to WM, follicular lymphoma, and marginal zone lymphoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.